Understanding how lung cancer changes its cell type to resist treatment
Project 2 - Epigenetic Drivers of Lineage Plasticity in Lung Cancer
This study is looking at how some lung cancers can change from one type to another when treated, and it's for people with lung cancer who want to understand why their tumors might not respond to therapy; researchers are using special techniques to see how certain genes play a role in this change.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11016330 on NIH RePORTER |
What this research studies
This research investigates the mechanisms behind lineage plasticity in lung cancer, particularly how certain lung cancer types can change from small cell lung cancer (SCLC) to lung adenocarcinoma (LUAD) in response to therapies. Using advanced genetic techniques, the study aims to identify the role of the epigenetic modifier EED in this transformation process. By creating genetically engineered mouse models, researchers will explore how changes at the genetic level influence tumor behavior and resistance to treatment. This work could provide insights into the tumor microenvironment and how it affects cancer progression.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with small cell lung cancer or lung adenocarcinoma who may be experiencing treatment resistance.
Not a fit: Patients with other types of cancer or those whose lung cancer is not resistant to current therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment strategies that effectively target the mechanisms of resistance in lung cancer.
How similar studies have performed: Previous research has shown promising results in understanding lineage plasticity in cancer, suggesting that this approach could yield valuable insights.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Oser, Matthew Gilbert — Dana-Farber Cancer Inst
- Study coordinator: Oser, Matthew Gilbert
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.